| Avalo Reports First Quarter 2025 Financial Results and Recent Business Updates |
WAYNE, Pa., May 12, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced business updates and financial results for the first quarter of 2025. |
globenewswire.com |
2025-05-12 11:00:00 |
Czytaj oryginał (ang.) |
| Avalo Therapeutics to Participate in The Citizens Life Sciences Conference |
WAYNE, Pa. and ROCKVILLE, Md., April 30, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced that Dr. Garry Neil, Chief Executive Officer of Avalo, will present at the Citizens Life Sciences Conference in New York on Thursday, May 8, 2025, at 3:00 pm ET. |
globenewswire.com |
2025-04-30 11:00:00 |
Czytaj oryginał (ang.) |
| Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board |
WAYNE, Pa. and ROCKVILLE, Md., March 26, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical-stage biotechnology company dedicated to treating immune dysregulation, today announced the appointment of Michael Heffernan as Chairman of the Board of Directors (“Board”). Mr. Heffernan will succeed Dr. Garry Neil as Chairman of the Board. Dr. Neil will continue as a Board member and Chief Executive Officer (CEO) of the Company. |
globenewswire.com |
2025-03-26 09:00:00 |
Czytaj oryginał (ang.) |
| Avalo Therapeutics 'Represents An Attractive Pure-Play,' Analyst Initiates Coverage With Over 300% Stock Upside |
On Monday, Stifel initiated coverage on Avalo Therapeutics, Inc. AVTX. Avalo's lead asset is AVTX-009, an anti-IL-1β mAb targeting inflammatory diseases. |
benzinga.com |
2025-03-25 17:20:44 |
Czytaj oryginał (ang.) |
| Avalo Reports 2024 Financial Results and Recent Business Updates |
Topline data from Phase 2 LOTUS Trial of AVTX-009 for the treatment of hidradenitis suppurativa expected in 2026 Appointed Jennifer Riley as Chief Strategy Officer Cash on hand of approximately $135 million as of December 31, 2024 expected to provide runway into at least 2027 WAYNE, Pa. and ROCKVILLE, Md. |
globenewswire.com |
2025-03-20 09:00:00 |
Czytaj oryginał (ang.) |
| Avalo Therapeutics to Participate in Upcoming Investor Conferences |
WAYNE, Pa. and ROCKVILLE, Md., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced that management will participate in the following investor conferences in March. |
globenewswire.com |
2025-02-24 09:00:00 |
Czytaj oryginał (ang.) |
| Avalo Therapeutics to Present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference |
WAYNE, Pa. and ROCKVILLE, Md. , Feb. 04, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced that Garry A. Neil, M.D., Chief Executive Officer and Chairman of the Board, will present at the virtual Oppenheimer 35th Annual Healthcare Life Sciences Conference on Tuesday, February 11, 2025 at 10:00 a.m ET. |
globenewswire.com |
2025-02-04 10:00:00 |
Czytaj oryginał (ang.) |
| Avalo Therapeutics Appoints Jennifer Riley as Chief Strategy Officer |
WAYNE, Pa. and ROCKVILLE, Md., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced the appointment of Jennifer Riley as Chief Strategy Officer, effective January 1, 2025. In this newly created role, Ms. Riley will oversee corporate strategy and commercial and product pipeline planning, with a goal of driving growth and innovation across the organization. |
globenewswire.com |
2025-01-02 09:00:00 |
Czytaj oryginał (ang.) |
| Avalo Therapeutics Receives $69.4 Million in Proceeds from the Full Exercise of Private Placement Warrants |
WAYNE, Pa. and ROCKVILLE, Md., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced that it has received $69.4 million in gross proceeds from the full exercise of the warrants issued in a March 2024 private placement. |
globenewswire.com |
2024-11-12 09:00:00 |
Czytaj oryginał (ang.) |
| Avalo Therapeutics to Present at Upcoming Investor Conferences |
WAYNE, Pa. and ROCKVILLE, Md., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced that Garry A. Neil, M.D., Chief Executive Officer and Chairman of the Board, will present at two upcoming investor conferences: |
globenewswire.com |
2024-11-11 09:00:00 |
Czytaj oryginał (ang.) |
| Avalo Announces First Patient Dosed in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa |
WAYNE, Pa. and ROCKVILLE, Md., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), today announced that the first patient has been dosed in the Company's Phase 2 LOTUS trial of AVTX-009 in hidradenitis suppurativa (HS). AVTX-009 is a humanized monoclonal antibody (IgG4) that binds to interleukin-1β (IL-1β) with high affinity and neutralizes its activity. |
globenewswire.com |
2024-10-08 11:00:00 |
Czytaj oryginał (ang.) |
| The 3 Best Personalized Nutrition Stocks to Buy Now |
It could be quite beneficial to invest in personalized nutrition stocks for this month in July. Some applications in the personalized nutrition market are now using artificial intelligence and machine learning, or ML, to provide consumers with more targeted and therefore better advice on their diet. |
investorplace.com |
2024-07-24 14:57:18 |
Czytaj oryginał (ang.) |
| Avalo Therapeutics Announces Appointment of Dr. Mittie Doyle as Chief Medical Officer |
WAYNE, Pa. and ROCKVILLE, Md., July 16, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) today announced that Mittie Doyle, MD, FACR has joined the Company as its Chief Medical Officer. |
globenewswire.com |
2024-07-16 11:00:00 |
Czytaj oryginał (ang.) |
| Avalo Therapeutics Announces Active IND for AVTX-009, an anti-IL-1β mAb, to Treat Hidradenitis Suppurativa |
WAYNE, Pa. and ROCKVILLE, Md., July 09, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) today announced that the Investigational New Drug (IND) for AVTX-009, an anti-IL-1β monoclonal antibody (mAb), for the treatment of hidradenitis suppurativa (HS) is now active, permitting the Company to commence its Phase 2 (LOTUS) clinical trial in patients with HS. Avalo expects to enroll the first patient in its Phase 2 LOTUS Trial this year. |
globenewswire.com |
2024-07-09 11:00:00 |
Czytaj oryginał (ang.) |
| Avalo Therapeutics Announces Appointment of Paul Varki as Chief Legal Officer |
WAYNE, Pa. and ROCKVILLE, Md., June 24, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) today announced that Paul Varki has joined the Company as its Chief Legal Officer. |
globenewswire.com |
2024-06-24 20:01:00 |
Czytaj oryginał (ang.) |
| Avalo to Present at the Oppenheimer Novel Targets in Immunology Summit |
WAYNE, Pa. and ROCKVILLE, Md., June 17, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) announced today that Garry A. Neil, M.D., Chief Executive Officer and Chairman of the Board, will present on the Novel Immunological Mechanisms for Dermatological Disorders Panel being held at 11:45 AM ET on June 24, 2024 at the Oppenheimer Novel Targets in Immunology Summit in New York, NY. |
globenewswire.com |
2024-06-17 11:30:00 |
Czytaj oryginał (ang.) |
| Is Avalo Therapeutics (AVTX) Stock Outpacing Its Medical Peers This Year? |
Here is how Avalo Therapeutics, Inc. (AVTX) and Annexon, Inc. (ANNX) have performed compared to their sector so far this year. |
zacks.com |
2024-05-22 14:40:34 |
Czytaj oryginał (ang.) |
| Avalo Reports First Quarter 2024 Financial Results and Provides Business Updates |
WAYNE, Pa. and ROCKVILLE, Md., May 13, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), today announced business updates and financial results for the first quarter of 2024. |
globenewswire.com |
2024-05-13 11:30:00 |
Czytaj oryginał (ang.) |
| Avalo Therapeutics (AVTX) Surges 270% in a Week: Here's Why |
Avalo (AVTX) surges on adding a new pipeline drug, which has its origins at Eli Lilly. Alongside the acquisition, it also secured funding to continue operations beyond 2027. |
zacks.com |
2024-04-02 16:31:03 |
Czytaj oryginał (ang.) |
| Avalo Therapeutics Appoints Biotech Leaders to Board of Directors |
WAYNE, Pa. and ROCKVILLE, Md., April 02, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) today announced the addition of multiple biotech leaders to its Board of Directors. The Avalo Board brings together a team with expertise spanning finance, business operations, drug discovery and clinical development. |
globenewswire.com |
2024-04-02 11:00:00 |
Czytaj oryginał (ang.) |
| Avalo Therapeutics (AVTX) stock slips after earnings: buy the dip? |
Avalo Therapeutics (AVTX) stock price nosedived on Monday after the company published relatively weak financial results. It tumbled by over 23.5% in the pre-market session and reached a low of $16.60. |
invezz.com |
2024-04-01 10:02:00 |
Czytaj oryginał (ang.) |
| Avalo Reports 2023 Financial Results and Provides Business Updates |
WAYNE, Pa. and ROCKVILLE, Md., March 29, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), today announced business updates and year-end financial results for 2023. |
globenewswire.com |
2024-03-29 18:01:00 |
Czytaj oryginał (ang.) |
| Why Is Avalo Therapeutics (AVTX) Stock Up 326% Today? |
Avalo Therapeutics (NASDAQ: AVTX ) stock is rocketing higher on Thursday after announcing a couple of positive updates for investors in the clinical-stage biotechnology company. The first big update worth noting is the company securing $185 million through a private placement. |
investorplace.com |
2024-03-28 10:04:38 |
Czytaj oryginał (ang.) |
| Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million |
WAYNE, Pa. and ROCKVILLE, Md., March 27, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) today announced it has acquired a Phase 2-ready anti-IL-1β mAb, which it refers to as AVTX-009, through the acquisition of privately held AlmataBio, Inc. Concurrent with the acquisition, Avalo entered into a definitive agreement for the sale of preferred stock and warrants in a private placement led by Commodore Capital and TCGX, with participation from BVF Partners, Deep Track Capital, OrbiMed, Petrichor, and RA Capital Management. The private placement will provide up to $185 million in gross proceeds, including an initial gross upfront investment of $115.6 million. After deducting estimated transaction costs from both the private placement financing and the acquisition of AlmataBio, Avalo expects net upfront proceeds to be approximately $105 million. The private placement is expected to close on March 28, 2024, subject to the satisfaction of customary closing conditions. Avalo intends to pursue the development of AVTX-009 in hidradenitis suppurativa (HS). Topline results from a planned Phase 2 trial in HS are expected in 2026 and the upfront funding is expected to fund operations through this data readout and into 2027. In addition to HS, Avalo intends to develop AVTX-009 in at least one other chronic inflammatory indication. |
globenewswire.com |
2024-03-27 18:01:00 |
Czytaj oryginał (ang.) |
| Will Avalo Therapeutics, Inc. (AVTX) Report Negative Q4 Earnings? What You Should Know |
Avalo Therapeutics (AVTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2024-03-27 13:02:05 |
Czytaj oryginał (ang.) |
| New Strong Buy Stocks for January 3rd |
GWRS, SRPT, AVTX, NTGR and PAY have been added to the Zacks Rank #1 (Strong Buy) List on January 3, 2024. |
zacks.com |
2024-01-03 10:16:12 |
Czytaj oryginał (ang.) |
| Avalo Therapeutics Announces 1-for-240 Reverse Stock Split |
WAYNE, Pa. and ROCKVILLE, Md., Dec. 27, 2023 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) today announced a 1-for-240 reverse stock split of the Company's common stock, par value $0.001, which will be effective at 5:00 pm Eastern Time on December 28, 2023. The Company's common stock will trade on the Nasdaq Capital Market on a split-adjusted basis beginning on December 29, 2023, under the Company's existing trading symbol “AVTX”. |
globenewswire.com |
2023-12-27 09:00:00 |
Czytaj oryginał (ang.) |